PL2895503T3 - Fibronectin based scaffold domain proteins that bind to myostatin - Google Patents

Fibronectin based scaffold domain proteins that bind to myostatin

Info

Publication number
PL2895503T3
PL2895503T3 PL13767190T PL13767190T PL2895503T3 PL 2895503 T3 PL2895503 T3 PL 2895503T3 PL 13767190 T PL13767190 T PL 13767190T PL 13767190 T PL13767190 T PL 13767190T PL 2895503 T3 PL2895503 T3 PL 2895503T3
Authority
PL
Poland
Prior art keywords
myostatin
bind
domain proteins
based scaffold
scaffold domain
Prior art date
Application number
PL13767190T
Other languages
Polish (pl)
Inventor
Sharon Cload
Linda Engle
Dasa Lipovsek
Malavi Madireddi
Ginger Chao RAKESTRAW
Joanna SWAIN
Wenjun Zhao
Hui WEI
Aaron P. Yamniuk
Alexander T. Kozhich
Vidhyashankar Ramamurthy
Martin J. Corbett
Stanley Richard KRYSTEK Jr.
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49253416&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2895503(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of PL2895503T3 publication Critical patent/PL2895503T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
PL13767190T 2012-09-13 2013-09-12 Fibronectin based scaffold domain proteins that bind to myostatin PL2895503T3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261700697P 2012-09-13 2012-09-13
US201361780005P 2013-03-13 2013-03-13
EP13767190.5A EP2895503B1 (en) 2012-09-13 2013-09-12 Fibronectin based scaffold domain proteins that bind to myostatin
PCT/US2013/059458 WO2014043344A1 (en) 2012-09-13 2013-09-12 Fibronectin based scaffold domain proteins that bind to myostatin

Publications (1)

Publication Number Publication Date
PL2895503T3 true PL2895503T3 (en) 2019-09-30

Family

ID=49253416

Family Applications (3)

Application Number Title Priority Date Filing Date
PL20206702.1T PL3835310T3 (en) 2012-09-13 2013-09-12 Fibronectin based scaffold domain proteins that bind to myostatin
PL19162848T PL3564258T3 (en) 2012-09-13 2013-09-12 Fibronectin based scaffold domain proteins that bind to myostatin
PL13767190T PL2895503T3 (en) 2012-09-13 2013-09-12 Fibronectin based scaffold domain proteins that bind to myostatin

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PL20206702.1T PL3835310T3 (en) 2012-09-13 2013-09-12 Fibronectin based scaffold domain proteins that bind to myostatin
PL19162848T PL3564258T3 (en) 2012-09-13 2013-09-12 Fibronectin based scaffold domain proteins that bind to myostatin

Country Status (33)

Country Link
US (9) US8853154B2 (en)
EP (4) EP4397675A3 (en)
JP (2) JP6346895B2 (en)
KR (3) KR102187714B1 (en)
CN (2) CN108409856B (en)
AU (2) AU2013315482B2 (en)
BR (1) BR112015005466B1 (en)
CA (1) CA2884730C (en)
CL (1) CL2015000500A1 (en)
DK (3) DK3835310T3 (en)
EA (1) EA033536B1 (en)
ES (3) ES2727453T3 (en)
FI (1) FI3835310T3 (en)
HR (3) HRP20240676T1 (en)
HU (3) HUE054699T2 (en)
IL (3) IL270110B (en)
LT (3) LT2895503T (en)
MX (2) MX390017B (en)
MY (2) MY172863A (en)
NZ (1) NZ628446A (en)
PE (1) PE20150954A1 (en)
PH (1) PH12015500397B1 (en)
PL (3) PL3835310T3 (en)
PT (3) PT2895503T (en)
RS (3) RS58801B1 (en)
SG (3) SG11201501741YA (en)
SI (3) SI3564258T1 (en)
SM (1) SMT202400214T1 (en)
TN (1) TN2015000086A1 (en)
TW (2) TWI633117B (en)
UY (2) UY40128A (en)
WO (1) WO2014043344A1 (en)
ZA (1) ZA201501457B (en)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2647846C (en) 2006-03-31 2016-06-21 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
RU2510400C9 (en) 2007-09-26 2014-07-20 Чугаи Сейяку Кабусики Кайся Modification method of isoelectric point of antibody by means of amino-acid replacements in cdr
TW201920257A (en) 2008-04-11 2019-06-01 日商中外製藥股份有限公司 Antigen-binding molecule capable of binding two or more antigen molecules repeatedly
WO2011150133A2 (en) * 2010-05-26 2011-12-01 Bristol-Myers Squibb Company Fibronectin based scaffold proteins having improved stability
SG10201509790YA (en) 2010-11-30 2015-12-30 Chugai Pharmaceutical Co Ltd Antigen-Binding Molecule Capable Of Binding To Plurality Of Antigen Molecules Repeatedly
US9469676B2 (en) 2011-04-13 2016-10-18 Bristol-Myers Squibb Company Fc fusion proteins comprising novel linkers or arrangements
TWI717591B (en) 2012-08-24 2021-02-01 日商中外製藥股份有限公司 Fcγ riib-specific fc region variant
US11236168B2 (en) 2012-08-24 2022-02-01 Chugai Seiyaku Kabushiki Kaisha Mouse FcγammaRII-specific Fc antibody
HRP20240676T1 (en) * 2012-09-13 2024-10-11 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind to myostatin
ES2715710T3 (en) 2013-01-25 2019-06-05 Shire Human Genetic Therapies Folistatin in the treatment of Duchenne muscular dystrophy
WO2014120891A2 (en) 2013-02-01 2014-08-07 Bristol-Myers Squibb Company Fibronectin based scaffold proteins
WO2014124017A1 (en) 2013-02-06 2014-08-14 Bristol-Myers Squibb Company Fibronectin type iii domain proteins with enhanced solubility
US10065987B2 (en) 2013-02-12 2018-09-04 Bristol-Myers Squibb Company High pH protein refolding methods
TWI636062B (en) 2013-04-02 2018-09-21 中外製藥股份有限公司 Fc region variant
PL3816625T3 (en) 2013-05-06 2026-01-26 Scholar Rock, Inc. GROWTH FACTOR MODULATION COMPOSITIONS AND METHODS
MX378753B (en) 2014-03-20 2025-03-10 Bristol Myers Squibb Co FIBRONECTIN TYPE III DOMAINS THAT BIND SERUM ALBUMIN.
JP6644701B2 (en) 2014-03-20 2020-02-12 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Stabilized fibronectin-based scaffold molecules
US10016394B2 (en) 2014-04-16 2018-07-10 The Scripps Research Institute PPARG modulators for treatment of osteoporosis
US11072681B2 (en) 2014-07-28 2021-07-27 The Regents Of The University Of California Compositions and methods of making polymerizing nucleic acids
WO2016023036A1 (en) 2014-08-08 2016-02-11 The Regents Of The University Of California High density peptide polymers
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
CN113929770A (en) 2014-11-21 2022-01-14 百时美施贵宝公司 Antibodies comprising modified heavy chain constant regions
KR102569813B1 (en) 2014-11-21 2023-08-24 브리스톨-마이어스 스큅 컴퍼니 Antibodies against cd73 and uses thereof
EP4218832A3 (en) 2014-11-25 2023-08-23 Bristol-Myers Squibb Company Methods and compositions for 18f-radiolabeling of the fibronectin type (iii) domain
CN107406494B (en) 2014-11-25 2022-03-25 百时美施贵宝公司 Novel PD-L1-binding peptides for imaging
KR102650420B1 (en) 2014-12-19 2024-03-21 추가이 세이야쿠 가부시키가이샤 Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
EA039219B1 (en) 2014-12-23 2021-12-20 Бристол-Майерс Сквибб Компани Antibodies to tigit
CN112142844B (en) 2015-02-05 2025-07-25 中外制药株式会社 Antibodies comprising ion concentration-dependent antigen binding domains, variants of the FC region, IL-8-binding antibodies and uses thereof
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US10993993B2 (en) * 2015-05-28 2021-05-04 Immunoforge Co., Ltd. Pharmaceutical composition for treating muscle atrophy or sarcopenia including glucagon-like peptide (GLP-1) or GLP-1 receptor agonist
JP6797137B2 (en) 2015-05-29 2020-12-09 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Antibodies to OX40 and its use
AU2016285920A1 (en) 2015-06-29 2018-02-01 Bristol-Myers Squibb Company Antibodies to CD40 with enhanced agonist activity
US20180228925A1 (en) * 2015-08-28 2018-08-16 University Of Massachusetts Quantifying Net Axonal Transport in Motor Neuron Pathologies
KR102818445B1 (en) * 2015-09-23 2025-06-10 브리스톨-마이어스 스큅 컴퍼니 Glypican-3-linked fibronectin-based scaffold molecule
CN108350416A (en) 2015-11-09 2018-07-31 百时美施贵宝公司 The method for manipulating the metric attribute of the polypeptide generated in Chinese hamster ovary celI
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
CA3016534A1 (en) 2016-03-04 2017-09-08 The Rockefeller University Antibodies to cd40 with enhanced agonist activity
US20190284293A1 (en) 2016-03-04 2019-09-19 Bristol-Myers Squibb Company Combination therapy with anti-cd73 antibodies
RU2613420C1 (en) * 2016-04-13 2017-03-16 Сергей Михайлович Юдин RECOMBINANT PROTEIN Mio-HSP, METHOD OF ITS PRODUCTION, INJECTION PREPARATION FOR MUSCLE MASS INCREASE IN FARM ANIMALS, BIRDS AND ANIMALS OF CANIDS, AS WELL AS METHOD OF USING PREPARATION
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
JP7106187B2 (en) 2016-05-11 2022-07-26 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ How to save the separation matrix
JP7031934B2 (en) 2016-05-11 2022-03-08 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ Separation matrix
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
ES2874974T3 (en) 2016-05-11 2021-11-05 Cytiva Bioprocess R & D Ab Separation matrix
ES2909833T3 (en) 2016-05-11 2022-05-10 Cytiva Bioprocess R & D Ab Cleaning and/or disinfection method of a separation matrix
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
WO2017210335A1 (en) 2016-06-01 2017-12-07 Bristol-Myers Squibb Company Imaging methods using 18f-radiolabeled biologics
US11344639B2 (en) 2016-06-01 2022-05-31 Bristol-Myers Squibb Company PET imaging with PD-L1 binding polypeptides
KR20190044070A (en) * 2016-08-03 2019-04-29 넥스트큐어 인코포레이티드 Composition and method for modulating LAIR signal transduction
MX2019001448A (en) 2016-08-05 2019-09-13 Chugai Pharmaceutical Co Ltd COMPOSITION FOR PROPHYLAXIS OR TREATMENT OF DISEASES RELATED TO INTERLEUKIN 8 (IL-8).
US12448411B2 (en) 2016-09-30 2025-10-21 Cytiva Bioprocess R&D Ab Separation method
US11331366B2 (en) 2016-12-05 2022-05-17 Otsuka Pharmaceutical Co., Ltd. Composition for suppressing muscular atrophy
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
TWI788340B (en) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 Anti-icos agonist antibodies and uses thereof
TWI897843B (en) * 2017-05-03 2025-09-21 美商必治妥美雅史谷比公司 Stable formulations of fibronectin based scaffold domain proteins that bind to myostatin
BR112019024419A2 (en) 2017-05-25 2020-07-14 Bristol-Myers Squibb Company antibodies comprising modified heavy constant regions
US11306149B2 (en) 2017-12-27 2022-04-19 Bristol-Myers Squibb Company Anti-CD40 antibodies and uses thereof
BR112020010536A2 (en) * 2018-01-25 2020-12-01 I-Mab Biopharma Us Limited fusion molecule, protein and cell isolated, composition and method to treat cancer
CN108593615A (en) * 2018-05-02 2018-09-28 浠思（上海）生物技术有限公司 The method for screening PD1/PD-L1 blocking agents using HTRF one-step method
JP7051656B2 (en) 2018-09-28 2022-04-11 三菱重工コンプレッサ株式会社 Turbine stators, steam turbines, and dividers
TW202033555A (en) 2018-11-16 2020-09-16 美商必治妥美雅史谷比公司 Anti-nkg2a antibodies and uses thereof
US20220106400A1 (en) 2018-11-28 2022-04-07 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
US12516145B2 (en) 2019-09-30 2026-01-06 Northwestern University Bioactive peptide brush polymers via photoinduced reversible-deactivation radical polymerization
KR20220151189A (en) 2020-03-09 2022-11-14 브리스톨-마이어스 스큅 컴퍼니 Antibodies to CD40 with enhanced agonist activity
WO2021231732A1 (en) 2020-05-15 2021-11-18 Bristol-Myers Squibb Company Antibodies to garp
US11566346B2 (en) 2020-06-25 2023-01-31 Philip David Rodley Protein scaffold
US20230416410A1 (en) * 2020-11-20 2023-12-28 Zoetis Services Llc Bovine antibody variants
WO2023196818A1 (en) 2022-04-04 2023-10-12 The Regents Of The University Of California Genetic complementation compositions and methods
WO2025177263A1 (en) 2024-02-25 2025-08-28 Biohaven Therapeutics Ltd. Myostatin-binding proteins
WO2025219859A1 (en) 2024-04-14 2025-10-23 Biohaven Therapeutics Ltd. Combination therapy to treat overweight, obesity, and related health conditions

Family Cites Families (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US5672502A (en) 1985-06-28 1997-09-30 Celltech Therapeutics Limited Animal cell culture
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US5589173A (en) 1986-11-04 1996-12-31 Genentech, Inc. Method and therapeutic compositions for the treatment of myocardial infarction
US5641648A (en) 1986-11-04 1997-06-24 Protein Polymer Technologies, Inc. Methods for preparing synthetic repetitive DNA
US6018030A (en) 1986-11-04 2000-01-25 Protein Polymer Technologies, Inc. Peptides comprising repetitive units of amino acids and DNA sequences encoding the same
US5770697A (en) 1986-11-04 1998-06-23 Protein Polymer Technologies, Inc. Peptides comprising repetitive units of amino acids and DNA sequences encoding the same
US5514581A (en) 1986-11-04 1996-05-07 Protein Polymer Technologies, Inc. Functional recombinantly prepared synthetic protein polymer
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
FR2646437B1 (en) 1989-04-28 1991-08-30 Transgene Sa NOVEL DNA SEQUENCES, THEIR APPLICATION AS A SEQUENCE ENCODING A SIGNAL PEPTIDE FOR THE SECRETION OF MATURE PROTEINS BY RECOMBINANT YEASTS, EXPRESSION CASSETTES, PROCESSED YEASTS AND PROCESS FOR PREPARING THE SAME
JP3051145B2 (en) 1990-08-28 2000-06-12 住友製薬株式会社 Novel polyethylene glycol derivative modified peptide
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5506134A (en) 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
US5792742A (en) 1991-06-14 1998-08-11 New York University Fibrin-binding peptide fragments of fibronectin
WO2002081494A1 (en) 2001-03-26 2002-10-17 Sirna Therapeutics, Inc. Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication
PL174494B1 (en) 1992-11-13 1998-08-31 Idec Pharma Corp Therapeutic application of chimeric and radiotracer labelled antibodies, directed against the differentation antigen limited to human lymphocytes b, for treating lymphoma from lymphocytes b
WO1994017097A1 (en) 1993-01-19 1994-08-04 Regents Of The University Of Minnesota Synthetic fibronectin fragments as inhibitors of retroviral infections
US6607884B1 (en) 1993-03-19 2003-08-19 The Johns Hopkins University School Of Medicine Methods of detecting growth differentiation factor-8
US20030074680A1 (en) 1993-03-19 2003-04-17 Johns Hopkins University School Of Medicine Growth differentiation factor-8
US6465239B1 (en) 1993-03-19 2002-10-15 The John Hopkins University School Of Medicine Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species
US7393682B1 (en) 1993-03-19 2008-07-01 The Johns Hopkins University School Of Medicine Polynucleotides encoding promyostatin polypeptides
EP1333035A3 (en) 1993-03-19 2004-07-07 The Johns Hopkins University School Of Medicine Growth differentiation factor-8
US5994618A (en) 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
US6673534B1 (en) 1995-10-26 2004-01-06 The Johns Hopkins University School Of Medicine Methods for detection of mutations in myostatin variants
US7332575B2 (en) 1994-03-18 2008-02-19 The Johns Hopkins University School Of Medicine Growth differentiation factor-8 nucleic acid and polypeptide from aquatic species, and transgenic aquatic species
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US6261804B1 (en) 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
PT971946E (en) 1997-01-21 2006-11-30 Gen Hospital Corp Selection of proteins using rna-protein fusions
WO1998033887A1 (en) 1997-02-05 1998-08-06 The Johns Hopkins University School Of Medicine Growth differentiation factor-8
US7749498B2 (en) 1997-03-10 2010-07-06 Genentech, Inc. Antibodies for inhibiting blood coagulation and methods of use thereof
CA2293632C (en) 1997-06-12 2011-11-29 Research Corporation Technologies, Inc. Artificial antibody polypeptides
WO1999051773A1 (en) 1998-04-03 1999-10-14 Phylos, Inc. Addressable protein arrays
WO1999056768A1 (en) 1998-05-06 1999-11-11 Metamorphix, Inc. Methods for treating diabetes by inhibiting gdf-8
US6818418B1 (en) * 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
DK1137941T4 (en) 1998-12-10 2014-01-06 Brystol Myers Squibb Company Protein scaffolds for antibody mimetics and other binding proteins
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US20050287153A1 (en) 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
AU4445601A (en) 2000-03-31 2001-10-08 Centre National De La Recherche Scientifique-Cnrs Peptides blocking vascular endothelial growth factor (vegf)-mediated angiogenesis, polynucleotides encoding said peptides and methods of use thereof
JP4578768B2 (en) 2000-07-11 2010-11-10 リサーチ コーポレイション テクノロジーズ，インコーポレイテッド Artificial antibody polypeptide
WO2002032925A2 (en) 2000-10-16 2002-04-25 Phylos, Inc. Protein scaffolds for antibody mimics and other binding proteins
US7598352B2 (en) 2000-11-17 2009-10-06 University Of Rochester Method of identifying polypeptide monobodies which bind to target proteins and use thereof
CA2443332A1 (en) 2001-04-04 2002-10-17 University Of Rochester .alpha..nu..beta.3 integrin-binding polypeptide monobodies and their use
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
WO2003104418A2 (en) 2002-06-06 2003-12-18 Research Corporation Technologies, Inc. Reconstituted polypeptides
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
ES2551682T3 (en) 2002-11-08 2015-11-23 Ablynx N.V. Single domain antibodies directed against tumor necrosis factor-alpha and uses for them
CN1946417A (en) 2003-12-05 2007-04-11 阿德内克休斯治疗公司 Inhibitors of type 2 vascular endothelial growth factor receptor
US20080220049A1 (en) 2003-12-05 2008-09-11 Adnexus, A Bristol-Myers Squibb R&D Company Compositions and methods for intraocular delivery of fibronectin scaffold domain proteins
HUE027902T2 (en) 2004-02-09 2016-11-28 Human Genome Sciences Inc Corp Service Company Albumin fusion proteins
BRPI0508716A (en) 2004-03-23 2007-08-07 Lilly Co Eli monoclonal antibody, process for producing the same, pharmaceutical composition, and use of a monoclonal antibody
WO2005118646A2 (en) 2004-04-26 2005-12-15 Centocor, Inc. Epitope directed selection of antibodies to murine tissue factor
KR101200133B1 (en) 2004-06-01 2012-11-13 제넨테크, 인크. Antibody drug conjugates and methods
CA2582374A1 (en) 2004-10-04 2006-04-20 Qlt Usa, Inc. Ocular delivery of polymeric delivery formulations
NZ538097A (en) 2005-02-07 2006-07-28 Ovita Ltd Method and compositions for improving wound healing
BRPI0610248A2 (en) 2005-04-25 2010-06-08 Pfizer antibodies to myostatin, pharmaceutical composition comprising them, cell lines producing them, nucleic acid molecules encoding them as well as their uses
EP3327033A1 (en) 2005-08-19 2018-05-30 Wyeth LLC Antagonist antibodies against gdf-8 and uses in treatment of als and other gdf-8-associated disorders
JP5052517B2 (en) 2005-10-06 2012-10-17 イーライ リリー アンド カンパニー Anti-myostatin antibody
UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
WO2007067616A2 (en) 2005-12-06 2007-06-14 Amgen Inc Uses of myostatin antagonists
US20070269422A1 (en) 2006-05-17 2007-11-22 Ablynx N.V. Serum albumin binding proteins with long half-lives
PT2066695E (en) 2006-09-05 2013-05-23 Lilly Co Eli Anti-myostatin antibodies
WO2008031098A1 (en) 2006-09-09 2008-03-13 The University Of Chicago Binary amino acid libraries for fibronectin type iii polypeptide monobodies
JP5537946B2 (en) 2006-11-22 2014-07-02 ブリストル−マイヤーズ スクイブ カンパニー Targeted therapeutic agents based on modified proteins for tyrosine kinase receptors including IGF-IR
WO2008097497A2 (en) 2007-02-02 2008-08-14 Adnexus, A Bristol-Myers Squibb R & D Company Vegf pathway blockade
EP2738257A1 (en) 2007-05-22 2014-06-04 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
US8680019B2 (en) 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
EP2222846B1 (en) 2007-08-10 2017-05-03 Protelix, Inc. Universal fibronectin type iii binding-domain libraries
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
JP2010538972A (en) 2007-08-20 2010-12-16 ブリストル−マイヤーズ スクイブ カンパニー Use of a VEGFR-2 inhibitor for the treatment of metastatic cancer
KR100857861B1 (en) * 2007-10-15 2008-09-11 주식회사 바이오리더스 Vector for surface expression of fusion protein of MYC-2 peptide polymer and myostatin and microorganism transformed with the vector
RU2010121967A (en) 2007-10-31 2011-12-10 Медиммун, Ллк (Us) PROTEIN FRAME FRAME STRUCTURES
PE20091163A1 (en) 2007-11-01 2009-08-09 Wyeth Corp ANTIBODIES FOR GDF8
EP2217274A1 (en) 2007-11-28 2010-08-18 Bristol-Myers Squibb Company Combination vegfr2 therapy with mtor inhibitors
JP2011507529A (en) 2007-12-19 2011-03-10 セントコア・オーソ・バイオテツク・インコーポレーテツド Alternative scaffold protein fusion phage display via fusion of M13 phage to pIX
JP2011507543A (en) 2007-12-27 2011-03-10 ノバルティス アーゲー Improved fibronectin-based binding molecules and their use
EP2080812A1 (en) 2008-01-18 2009-07-22 Transmedi SA Compositions and methods of detecting post-stop peptides
KR20100128291A (en) 2008-02-14 2010-12-07 브리스톨-마이어스 스큅 컴퍼니 Targeted Therapeutics Based on Engineered Proteins That Bind to EVFR
JP6192891B2 (en) 2008-05-02 2017-09-06 ノバルティス アーゲー Improved fibronectin-based binding molecules and their use
AR071874A1 (en) 2008-05-22 2010-07-21 Bristol Myers Squibb Co ARMAZON DOMAIN PROTEINS BASED ON MULTIVALENT FIBRONECTINE
CN102307896B (en) 2008-10-31 2016-10-12 森托科尔奥索生物科技公司 Type III fibronectin domain-based scaffold compositions, methods and uses
US8415291B2 (en) 2008-10-31 2013-04-09 Centocor Ortho Biotech Inc. Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
TWI496582B (en) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 Bispecific egfr/igfir binding molecules
JP5985826B2 (en) 2008-12-16 2016-09-06 ノバルティス アーゲー Yeast display system
AR074777A1 (en) 2008-12-19 2011-02-09 Glaxo Group Ltd PROTEINS OF UNION TO ANTIGEN
WO2010093771A1 (en) 2009-02-11 2010-08-19 Bristol-Myers Squibb Company Combination vegfr2 therapy with temozolomide
CN102596992B (en) 2009-02-12 2015-09-09 詹森生物科技公司 Based on the holder combination thing of III type fibronectin domain, method and purposes
US8067201B2 (en) 2009-04-17 2011-11-29 Bristol-Myers Squibb Company Methods for protein refolding
WO2011020033A2 (en) 2009-08-13 2011-02-17 Massachusetts Institute Of Technology Engineered proteins including mutant fibronectin domains
WO2011051333A1 (en) 2009-10-30 2011-05-05 Novartis Ag Universal fibronectin type iii bottom-side binding domain libraries
WO2011051466A1 (en) 2009-11-02 2011-05-05 Novartis Ag Anti-idiotypic fibronectin-based binding molecules and uses thereof
US20110123545A1 (en) 2009-11-24 2011-05-26 Bristol-Myers Squibb Company Combination of vegfr2 and igf1r inhibitors for the treatment of proliferative diseases
WO2011092233A1 (en) 2010-01-29 2011-08-04 Novartis Ag Yeast mating to produce high-affinity combinations of fibronectin-based binders
US8961977B2 (en) 2010-02-12 2015-02-24 University Of Rochester Antigenic mimics of discontinuous epitopes of pathogen recognized by broadly neutralizing antibodies
US8927693B2 (en) 2010-02-18 2015-01-06 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind IL-23
JP2013523179A (en) 2010-04-13 2013-06-17 メディミューン，エルエルシー Multimeric scaffolds based on fibronectin type III domains
CN105175532B (en) * 2010-04-13 2023-01-17 百时美施贵宝公司 A fibronectin-based scaffold domain protein that binds PCSK9
SI2571531T1 (en) 2010-04-30 2016-09-30 Janssen Biotech, Inc. Stabilized fibronectin domain compositions, methods and uses
TW201138808A (en) 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
JO3340B1 (en) 2010-05-26 2019-03-13 Regeneron Pharma Antibodies to human gdf8
WO2011150133A2 (en) 2010-05-26 2011-12-01 Bristol-Myers Squibb Company Fibronectin based scaffold proteins having improved stability
RU2013108962A (en) 2010-07-30 2014-09-10 Новартис Аг FIBRONECTIN MOLECULES CONTAINING A POCKET AND THEIR LIBRARIES
SG10201506405YA (en) 2010-08-16 2015-10-29 Amgen Inc Polypeptides That Bind Myostatin, Compositions And Methods
EP2655411A1 (en) * 2010-12-22 2013-10-30 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind il-23
US9469676B2 (en) 2011-04-13 2016-10-18 Bristol-Myers Squibb Company Fc fusion proteins comprising novel linkers or arrangements
WO2012158678A1 (en) 2011-05-17 2012-11-22 Bristol-Myers Squibb Company Methods for maintaining pegylation of polypeptides
WO2012158739A1 (en) 2011-05-17 2012-11-22 Bristol-Myers Squibb Company Improved methods for the selection of binding proteins
KR102035713B1 (en) 2011-09-27 2019-10-24 얀센 바이오테크 인코포레이티드 Fibronectin type iii repeat based protein scaffolds with alternative binding surfaces
AU2013274347B2 (en) 2012-06-11 2018-03-08 Amgen Inc. Dual receptor antagonistic antigen-binding proteins and uses thereof
MX364738B (en) 2012-06-15 2019-05-03 Pfizer Improved antagonist antibodies against gdf-8 and uses therefor.
HRP20240676T1 (en) * 2012-09-13 2024-10-11 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind to myostatin
TWI897843B (en) 2017-05-03 2025-09-21 美商必治妥美雅史谷比公司 Stable formulations of fibronectin based scaffold domain proteins that bind to myostatin

Also Published As

Publication number Publication date
KR102187714B1 (en) 2020-12-07
TN2015000086A1 (en) 2016-06-29
SI3835310T1 (en) 2024-07-31
US11813315B2 (en) 2023-11-14
US20140107020A1 (en) 2014-04-17
MX2019008391A (en) 2019-09-09
KR102424590B1 (en) 2022-07-27
SG10201913685YA (en) 2020-03-30
TW201823269A (en) 2018-07-01
HRP20240676T1 (en) 2024-10-11
SI3564258T1 (en) 2021-07-30
ES2727453T3 (en) 2019-10-16
IL270110A (en) 2019-12-31
CN104768969A (en) 2015-07-08
EP3564258A1 (en) 2019-11-06
TWI633117B (en) 2018-08-21
PT2895503T (en) 2019-06-03
US8853154B2 (en) 2014-10-07
JP6346895B2 (en) 2018-06-20
CA2884730A1 (en) 2014-03-20
HRP20210990T1 (en) 2021-09-17
EP3835310B1 (en) 2024-03-20
IL237559B (en) 2019-10-31
AU2013315482B2 (en) 2018-03-15
US20190307855A1 (en) 2019-10-10
ES2984405T3 (en) 2024-10-29
US20240316161A1 (en) 2024-09-26
UY40128A (en) 2023-04-28
WO2014043344A1 (en) 2014-03-20
PE20150954A1 (en) 2015-06-20
PL3835310T3 (en) 2024-06-03
DK2895503T3 (en) 2019-05-27
US9493546B2 (en) 2016-11-15
HUE043482T2 (en) 2019-08-28
AU2018201273B2 (en) 2020-04-09
IL294314A (en) 2022-08-01
KR20200138435A (en) 2020-12-09
US20140105896A1 (en) 2014-04-17
JP2018183138A (en) 2018-11-22
KR102751864B1 (en) 2025-01-07
PT3835310T (en) 2024-05-20
PH12015500397A1 (en) 2015-04-27
IL294314B1 (en) 2026-02-01
NZ800822A (en) 2025-02-28
CN108409856B (en) 2022-03-04
US10406212B2 (en) 2019-09-10
US9662373B2 (en) 2017-05-30
US20170088602A1 (en) 2017-03-30
DK3564258T3 (en) 2021-06-21
MY189682A (en) 2022-02-25
NZ628446A (en) 2017-06-30
EA201590543A1 (en) 2015-06-30
EP3835310A1 (en) 2021-06-16
FI3835310T3 (en) 2024-05-31
MX2015002894A (en) 2015-06-03
EP4397675A3 (en) 2024-10-16
AU2013315482A1 (en) 2015-03-12
UY35027A (en) 2014-03-31
LT3564258T (en) 2021-08-25
RS58801B1 (en) 2019-07-31
IL270110B (en) 2022-08-01
EA033536B1 (en) 2019-10-31
HRP20190845T1 (en) 2019-08-09
IL237559A0 (en) 2015-04-30
EP4397675A2 (en) 2024-07-10
SI2895503T1 (en) 2019-08-30
CN104768969B (en) 2021-04-16
LT2895503T (en) 2019-07-25
MY172863A (en) 2019-12-13
LT3835310T (en) 2024-04-25
ES2879387T3 (en) 2021-11-22
US8933199B2 (en) 2015-01-13
JP6793680B2 (en) 2020-12-02
CL2015000500A1 (en) 2015-07-31
SG11201501741YA (en) 2015-04-29
MX366666B (en) 2019-07-19
TW201416376A (en) 2014-05-01
US20140309163A1 (en) 2014-10-16
TWI694085B (en) 2020-05-21
KR20220107082A (en) 2022-08-01
EP2895503B1 (en) 2019-03-27
ZA201501457B (en) 2021-09-29
DK3835310T3 (en) 2024-06-03
HUE067383T2 (en) 2024-10-28
RS62009B1 (en) 2021-07-30
AU2018201273A1 (en) 2018-03-15
HK1212717A1 (en) 2016-06-17
EP3564258B1 (en) 2021-04-28
PL3564258T3 (en) 2021-10-25
JP2015530390A (en) 2015-10-15
SG10201701970TA (en) 2017-05-30
HUE054699T2 (en) 2021-09-28
CN108409856A (en) 2018-08-17
EP2895503A1 (en) 2015-07-22
BR112015005466B1 (en) 2023-04-11
US10245302B2 (en) 2019-04-02
PT3564258T (en) 2021-06-30
SMT202400214T1 (en) 2024-07-09
US8993265B2 (en) 2015-03-31
KR20150054938A (en) 2015-05-20
RS65556B1 (en) 2024-06-28
US20150072919A1 (en) 2015-03-12
BR112015005466A2 (en) 2017-08-08
US20170354718A1 (en) 2017-12-14
CA2884730C (en) 2023-07-04
US20150231211A1 (en) 2015-08-20
MX390017B (en) 2025-03-11
PH12015500397B1 (en) 2021-02-19

Similar Documents

Publication Publication Date Title
IL294314B1 (en) Fibronectin based scaffold domain proteins that bind to myostatin
ZA201408580B (en) Detergent composition
ZA201206969B (en) Fibronectin based scaffold domain proteins that bind il-23
PL2662436T3 (en) Detergent composition
ZA201500575B (en) Adw detergent composition
IL235299B (en) Injectable preparation
SG11201504939RA (en) Microcontroller
BR302013002335S1 (en) CONFIGURATION APPLIED TO OBJECT HOLDERS
EP2861068A4 (en) Methods related to bevacizumab
EP2856158A4 (en) Methods related to rituximab
BR112015012440A2 (en) cleaning composition
GB2507762B (en) Improvements to dartboards
GB201215288D0 (en) Improvements relating to firelighters
GB201206287D0 (en) Bid to rent property
ZA201504070B (en) Detergent composition
BR302012002575S1 (en) CONFIGURATION APPLIED TO MUG
BR302012004065S1 (en) CONFIGURATION APPLIED TO ME ANATOMIC CONTAINER
GB201201142D0 (en) Sdd